Newly activated UI Cancer Center clinical trials

Newly activated UI Cancer Center clinical trials

The following studies have recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on ClinicalTrials.gov. For more information or questions about a study, please email cancertrials@uic.edu or call 312-355-5112.

 

RiMO: Phase 1 Dose-Escalation Study of RiMO-2 with Radiation in Advanced Tumors
https://clinicaltrials.gov/ct2/show/NCT03444714
Principal Investigator: Lawrence Feldman, MD
Research Sponsor: RiMO Therapeutics, Inc.

 

NRG-G1004: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch repair (dMMR) Metastatic Colorectal Cancer
https://clinicaltrials.gov/ct2/show/NCT02997228
Principal Investigator: Neeta Venepalli, MD
Research Sponsor: NRG Oncology

 

A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST): A screening trial for A081105, E4512 and EA5142
https://clinicaltrials.gov/ct2/show/NCT02194738
Principal Investigator: Ardaman Shergill, MC
Research Sponsor: Alliance

 

NRG-GU006: A Phase II, Double-blinded, Placebo-controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT03371719
Principal Investigator: David Peace, MD
Research Sponsor: NRG Oncology

Leave a reply

Your email address will not be published. Required fields are marked *